The mission of the Melanoma Research Alliance (MRA) is to end suffering and death due to melanoma by collaborating with all stakeholders to accelerate powerful research, advance cures for all patients, and prevent more melanomas.

Founded in 2007 by melanoma survivor Debra Black and her husband, Leon, under the auspices of the Milken Institute, MRA has ushered in a dynamic new era of scientific progress. MRA has become the largest non-profit funder of melanoma research, funding $101 million in cutting-edge studies and leveraging millions more from other sources during the last decade. Thanks to the generous support of our founders, 100% of all donations to MRA go directly to research.
In 2007, when the Melanoma Research Alliance was established, the prognosis for metastatic melanoma was bleak. The two FDA-approved medications that did exist were not very effective and research on melanoma had stalled. The last drug to be approved by the FDA was in 1998 and for those facing a late-stage melanoma diagnosis there was little hope.

More than ten years later, the field could not be more different. With the support of MRA, a new paradigm of promising research has advanced and drug discovery has transformed not only the way we treat melanoma but all of oncology. Patients with a diagnosis of late-stage melanoma now have 12 more FDA approved treatments – new options that not only offer improved outcomes, but renewed hope. The energy, excitement and ideas that have transformed melanoma continue to grow – and today more than 500 clinical trials are focused on finding the next promising treatments.

MRA has directly invested more than $101 million in cutting-edge melanoma research world-wide and has leveraged an additional $101 million from other sources. All MRA funded research is vetted by our grant review committee of world-renowned scientists and researchers.

The world has changed for many melanoma patients – but still it is not enough.

It is estimated that 91,000 Americans will be diagnosed with melanoma this year. Even worse, more than 9,000 people are predicted to die from this disease. Every day we hear from patients that are not responding to even the most innovative therapies. These sobering statistics and stories motivate us to continue our mission of fast forwarding the research and ending death and suffering due to melanoma.
MRA is committed to funding the most promising research globally and to partner with all stakeholders.

MRA is proud to showcase many key achievements from the past year. MRA remains deeply grateful to the many donors, organizations, government officials, corporations, researchers and patients who have joined us in our shared mission to eradicate melanoma. Our work would not be possible without you.

Many Thanks.

[Signatures]

Debra Black
Chair and Co-Founder

Michael Kaplan
President and CEO
CONNECTING THE DOTS

“The Melanoma Research Alliance has a unique vision and approach in bringing together all key stakeholders to advance treatment options and prevention strategies for melanoma. Through their engagement with patients and families, investigators, industry partners, and regulatory agencies, they empower us to work together as a team to optimally advance the field.”

– Dr. Jennifer Wargo, MD Anderson Cancer Center
Breaking Ground and Building Partnerships

Since its founding in 2007, the Melanoma Research Alliance (MRA) has played a pivotal role in the global response to melanoma. MRA has helped transform the landscape for melanoma research from minimal investment and activity to one of momentous excitement and breakthroughs. The Alliance’s roadmap for success is based on a clear mission and a deliberate approach: to work with all stakeholders to better prevent, detect, treat, and eventually cure melanoma.

MRA is clear of its role; making science the crown jewel of all they do, but also knowing investment in science alone will not get the needed results. The true power of their research is made evident when the dots get connected. MRA’s investment in research is unparalleled, yet equally important is MRA’s role as a champion and convener of the field at-large. Industry, nonprofits, researchers, government, patients, and families are all critical in the fight against melanoma. That’s why MRA is so focused on connecting the dots.

Its web address with “cure melanoma” and its inclusion of “alliance” in its name are not coincidences but, rather, intentional choices to stay focused on the task at hand and ensure tomorrow is even more promising than today.

Each and every year since its founding, MRA has leveraged its immense convening power through their Scientific Retreat (www.curemelanoma.org/research/scientific-retreat/2018/). A retreat where stakeholders can come together to learn from one another’s efforts and, ultimately, propel the field forward—surpassing what any single player could have done alone. And as momentum grows, so too does the impact.

The interdependence is undeniable. The success of clinical trials depend upon researchers and patients alike. Expanding available treatments requires not only discovery, bench research and trials; but also regulatory approval. To increase awareness about melanoma means advocacy, and to do so effectively means galvanizing voices across all sectors, in every corner of the globe.

MRA’s investment in the science, combined with their understanding and support of the critical inter-plays of research with patient engagement, regulatory systems, industry and more has provided dramatic results. In fact, since MRA’s founding in 2007, there have been 12 new melanoma treatments approved by the FDA, and many more are being studied. And most importantly, patients are living longer thanks to the advancements in research.
Connecting the Dots Between Patients and Research

The connection between patients and research seems obvious. Patients win when research delivers new and better treatment options. However, the relationship does not flow in just one direction. It is a reciprocal relationship, as research would not be possible without patient volunteers. Put simply, patients need research, but research also needs patients.

MRA is committed to helping patients and their families understand how research affects them and their treatment decisions, and how patients help to advance research. In 2017, MRA made considerable progress in connecting these dots with the launch of two new tools, the Melanoma > Exchange and the Clinical Trial Navigator. These tools bring MRA’s work full circle from helping to develop new treatment approaches to helping patients understand and find the best option for them, while also helping patients advance research.

Melanoma > Exchange

Join the Conversation

The Melanoma > Exchange is a free and open online community dedicated melanoma treatment and research focused discussion group and support community.

MRA's Clinical Trial Navigator

powered by Antidote

MRA's Clinical Trial Navigator is the easiest way for patients to quickly match themselves to clinical trials in their community.
Finding the Connections Across Varied Avenues of Research

MRA’s investment in research and convening power has strengthened collaborations among scientists and physicians from across multiple fields of medical study. As MRA connects the dots and propels the field forward, new opportunities and advancements arise. For example, targeted therapy that capitalizes on specific mutations in patients’ melanoma is a leading example of personalized medicine. And immunotherapy has not only dramatically changed the melanoma treatment landscape, but is now being used to treat nine other cancers and tested in many more.

Yet for some patients, immunotherapy isn’t the answer, and for others, it may be simply one part of a more complex solution. Further study is needed, looking at everything from bio-markers for treatment selection, to ensuring tumors are recognized by the immune system; and from new treatment combinations to understanding ideal sequencing and timing of treatment for each and every patient.

MRA’s scientific investments are both broad and diverse, knowing that the answers may not reside squarely in one field of study. MRA has funded research on 96 different investigational agents to date, and on approaches as varied as artificial intelligence for better detection to radiation for turning a tumor hot. Past research opens new windows of exploration, with each discovery providing new avenues of hope.

One example of this can be seen in research focused on the microbiome. Research supported by MRA and conducted by Dr. Tom Gajewski from 2013 to 2016 further demonstrated that treatment and cancer type alone do not define patient outcomes. Instead, a more complex picture is at play, once again, denoting a need to connect all the dots. With research supported by MRA at the University of Chicago, Dr. Gajewski published seminal articles that helped to explore and define the role of the microbiome in melanoma treatment.

**mi·cro·bi·ome**

- a community of **microorganisms** (such as bacteria, fungi, and viruses) that inhabit a particular environment and especially the collection of microorganisms living in or on the human body
- the collective **genomes** of microorganisms inhabiting a particular environment and especially the human body
- the full genetic complement of bacteria and other organisms at home on your skin, gums, and teeth, in your genital tract, and especially in your gut.

(www.merriam-webster.com/dictionary/microbiome)
The implications of this research are numerous and far reaching. For example:

- Should doctors be profiling the gut microbiome of patients with cancer going into treatment?
- Should doctors be closely monitoring factors that impact the microbiome in patients (e.g., antibiotic use, diet, probiotic use)?
- Should there be close monitoring of the gut microbiome in pre-clinical models for cancer therapy?
- Can the gut microbiome be modulated to enhance therapeutic responses and to abrogate toxicity and, if so, how should this be done?
- Which diets or probiotics may be helpful and which may be harmful?

Answering these questions, and so many others, necessitates connecting the dots.

While Gajewski launched studies demonstrating a role for the gut microbiome in response to immune checkpoint blockade in melanoma mouse models, Dr. Jennifer Wargo of M.D. Anderson Cancer Center studied the gut microbiome in patients and compared those that were responding well to therapy versus the microbiome of people who weren’t responding.

Wargo and team were able to demonstrate that a “favorable” gut microbiome was associated with improved systemic and anti-tumor immune responses, suggesting that the two are linked. “This area of focus is novel and game-changing for cancer treatment, as immune responses are critical to virtually every form of cancer therapy,” says Wargo.

Today, this early area of exploration continues to greatly expand as does MRA’s investment, with two new team awards issued in 2018 looking at the impact of microbiome on treatment, and the impact of diet and mental health on the microbiome.
## BY THE NUMBERS

### Seeing the Big Picture

It’s amazing to think of the breakthroughs of today and the implications that melanoma research has on the broader cancer and health fields when just 11 years ago, little investment and research was happening at all. To date, MRA has invested and funded the following:

<table>
<thead>
<tr>
<th>Category</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Million in Grants</td>
<td>$101</td>
</tr>
<tr>
<td>Investigators</td>
<td>372</td>
</tr>
<tr>
<td>Research Awards Issued</td>
<td>266</td>
</tr>
<tr>
<td>Million in Leveraged Funds</td>
<td>$101</td>
</tr>
<tr>
<td>Donors</td>
<td>5700</td>
</tr>
<tr>
<td>Institutions in 15 Countries Funded</td>
<td>126</td>
</tr>
<tr>
<td>Different Agents for Treatment of Melanoma Investigated</td>
<td>96</td>
</tr>
<tr>
<td>Corporate Partners Who’ve Raised $40.3 Million to Support Melanoma Research</td>
<td>442</td>
</tr>
</tbody>
</table>

100% of all donations go directly to research – no admin, development, or other fees.
Expanding the Network

The MRA approach encourages others to join the fight, too—not as competitors but, as allies. Take Tracy Callahan. Tracy was a registered research nurse when she was diagnosed with melanoma. In total, she has been diagnosed four times, though all thankfully caught early. Inspired by the name “Polka Dot Mama,” given to her by her two boys, Tracy began to network with survivors and skin care organizations around the country. A few months in, Tracy got the idea to create her own nonprofit called the Polka Dot Mama Melanoma Foundation (www.polkadotmama.org). Only she didn’t know where to start.

What she knew was that she had a voice and she wanted to use it. The message? Melanoma prevention, awareness, education, and research. Tracy spoke with her contacts at Duke University who encouraged her to pick up the phone and call MRA. Tracy spoke with MRA’s President & CEO and its Chief Science Officer. “I told them my idea for a nonprofit and from that moment they embraced me with open arms,” says Tracy. “They asked how they could help.”

At a recent Scientific Retreat, Tracy was learning about advances in treatment science, networking with researchers and other advocates, and dreaming new ideas for her nonprofit. A conversation that began with an “If only…” ended with a donated school bus to Tracy’s nonprofit that she has since converted into the Shade Shuttle, allowing her to provide free skin cancer checks in rural communities throughout North Carolina.

In addition to the critical work she’s doing to educate her community about sun safety and the importance of skin checks, Tracy has also helped advance the science by donating to MRA’s research efforts. Since 2016, Tracy and the Polka Dot Mama Foundation have donated $40,000 to support MRA’s research program, a donation that will go directly to research funded through MRA’s expert peer-review process, with no admin or development expenses reducing the impact of her donation.

“The more I do research, the more I can tell you that there is no other organization I know of that you can pick up the phone and talk to the Chief Science Officer about your unique case. It may seem small, but for a patient, it’s huge,” says Tracy.

Tracy’s leadership is not only felt in her community, but also on the national stage. She recently helped MRA launch the Melanoma > Exchange online community as one of its four inaugural Community Leaders.

“If I can make a difference in someone’s life by sharing my journey, then these scars will be given purpose,”

– Tracy Callahan, Founder of Polka Dot Mama Melanoma Foundation
Kinetic Energy: Driving the Field...

MRA brings more than hope. It brings a promise to facilitate connections within and across disciplines and industries, to accelerate new research and methodologies, and to amplify messages of prevention and awareness.

But fulfilling this promise doesn’t just happen. It’s more than putting people in touch or putting people in a room. It must be proactively made to happen – the dots have to be connected and aligned. In that way, MRA has been a kinetic force in this field. It means connecting a patient to not just a trial but the right trial so that one day they can hear those sweet words: no evidence of disease. It means connecting a researcher not just to any funder but the right biotech partner to breathe life into their vision and then to bring it to scale. It means with each dream achieved, dreaming of another because we don’t yet have a cure—but we do have new treatments, new partnerships, new knowledge, and more momentum than ever to find one. And with this alliance that’s growing bigger and bigger every day, we’re stronger than ever.

This is the essence of the MRA. This is its vision and mission in action.
Since its founding in 2007, MRA has awarded more than $101 million for 266 research programs with the potential to make significant, near-term clinical impact in melanoma prevention, diagnosis, staging, and treatment. The following are new grants issued in 2018 in response to three different funding opportunities:

- Special funding initiative focused on acral melanoma,
- MRA joint grant making partnership with the American Cancer Society (ACS) to address adverse events related to checkpoint immunotherapy, and
- MRA’s annual request for proposals.

A complete list of all MRA grantees, along with grant abstracts, can be found at www.curemelanoma.org/research/mra-research-awards.

**MRA Acral Melanoma Special Opportunity Awards**

Acral melanoma is a rare and difficult-to-treat form of melanoma that arises on the palm, sole or beneath the nail. Acral melanoma accounts for approximately 2-3% of all melanomas and its incidence is relatively constant across individuals of all races and skin colors. Compared to cutaneous melanoma, acral melanoma is more likely to be diagnosed at a later stage and has a survival rate that is 10-20% lower, overall. In fall of 2017, MRA released a Special Opportunity Request for Proposals inviting applications for both Team Science (up to $900,000 over 3-years) and Individual Investigator Awards (up to $225,000 over 3-years) that could lead to therapeutic targeting of acral melanoma with priority given to proposals that of focus on NF1 loss, TERT promoter alterations, CCND1, and/or CRKL amplification. As a result, the following awards were issued in 2018:
**Telomere crisis in acral melanoma: Diagnostic and prognostic potentials:** Takes a look at acral melanomas on the chromosome level to determine whether a process known as telomere crisis, which causes extensive damage to a cell’s genome, contributes to acral melanoma development and progression.

The Black Family-MRA Team Science Award
- Titia de Lange, Ph.D., The Rockefeller University
- Marcin Imieliński, M.D., Ph.D., Joan Sanford I. Weill Medical College of Cornell
- John Maciejowski, Ph.D., Memorial Sloan Kettering Cancer Center: Young Investigator

**Defining and targeting driver events in acral melanoma:** Seeks to address some of the major barriers to new therapies for acral melanoma by developing a novel mouse model, as well as studying the genetic processes linked to tumor development.

U.S. Trust-MRA Team Science Award
Lee Moffitt Cancer Center & Research Institute
- Keiran Smalley, Ph.D.
- Yian Chen, Ph.D.
- John Koomen, Ph.D.
- Jane Messina, M.D.
- Jamie Teer, Ph.D.
- Florian Karreth, Ph.D.

**Patient-focused therapy for acral melanoma:** Aims to take a precision medicine approach to better suppress acral melanoma growth and spread by matching drugs to the specific genetic and/or genomic changes present in a patient’s tumor.

The Sokoloff Family-MRA Team Science Award, with collaborative funding from Memorial Sloan Kettering Cancer Center

Yale University
- Ruth Halaban, Ph.D.
- Alfred Bothwell, Ph.D.
- Jian Cao, Ph.D.
- Qin Yan, Ph.D.

Memorial Sloan Kettering Cancer Center
- Charlotte Ariyan, M.D., Ph.D.
- Neal Rosen, M.D., Ph.D.
- Richard White, M.D., Ph.D.
- Jedd Wolchok, M.D., Ph.D.
- Gauri Panse, M.D., Young Investigator

**Regulating telomerase and telomere homeostasis in acral melanoma development:** Plans to create new models to better study the telomerase gene (TERT), a main cause of mutations and other genomic alterations in cancer cells, including acral melanoma, to find approaches to treat cells with TERT abnormalities.

MRA Team Science Award, collaboratively funded by the research institutions
The Pennsylvania State University College of Medicine
- Gavin P. Robertson, Ph.D.
- Raghavendra Gowda, Ph.D., Young Investigator

Washington State University
- Jiyue Zhu, Ph.D.
- De Cheng, Ph.D.
- Shobhan Gaddameedhi, Ph.D., Young Investigator
Molecular and immune profiling of acral melanoma from various ethnicities: Will combine clinical, histological, immune, and molecular analyses of acral melanoma patients from different ethnicities to better classify risks among each group.

MRA Young Investigator Award, collaboratively funded by University of Texas M.D. Anderson Cancer Center
- Phyu Aung, M.D., Ph.D.,

A novel approach for NF1 mutant melanoma subclassification: Utilizes a unique mathematical model to determine whether (and how) melanomas with a mutation in a gene called NF1 should be further classified, ultimately providing information about this subset of melanoma patients’ response and resistance to targeted therapies.

MRA Young Investigator Award
- Edward Cooper Stites, M.D., Ph.D., The Salk Institute for Biological Studies

MRA/ACS Jointly Funded Awards
Addressing Adverse Events Related to Checkpoint Immunotherapy

Immunotherapies have played a critical role in advancing melanoma treatment and melanoma has also served as the proving ground for immunotherapy. Checkpoint immunotherapies, while first approved in melanoma, are now being used to treat many more cancers. While these treatments are well-tolerated by most, some experience life-altering and occasionally life-threatening adverse events. In recognition of the immense potential of checkpoint immunotherapies in combatting multiple cancers, and the reality that immune-related adverse events pose a challenge that must be addressed, MRA and ACS issued a joint Request for Proposals in summer of 2017 inviting applications for both Team Science (up to $1 million over 3 years) and Pilot Awards (up to $200,000 over 2 years) focused on the prevention, reduction, and/or management of life-altering and/or outcome-limiting side-effects of checkpoint inhibitor therapy. As a result, the following awards were issued in 2018:
**Genetic and phenotypic biomarkers to predict immune-related adverse events:** Will enroll and analyze patients with melanoma and other cancers undergoing immunotherapy to determine if latent autoimmunity increases the risk of immune-related adverse events.

**MRA-ACS Team Science Award**
University of Texas Southwestern Medical Center

- David Gerber, M.D.
- Edward Wakeland, Ph.D.
- Quan-Zhen Li, M.D., Ph.D.
- Yang Xie, Ph.D., MPH
- Jade Homsi, M.D.

**Discovery of therapeutic approaches for ipilimumab-associated colitis:** Will conduct a clinical trial to study two separate treatment options, and determine the best treatment for preserving the anti-tumor immune response, in melanoma patients who experience ipilimumab-associated colitis.

**MRA-ACS Team Science Award**
Dana-Farber Cancer Institute

- Kai Wucherpfennig, M.D., Ph.D.
- Guo-Cheng, Ph.D.

**Understanding cutaneous immunotherapy-related adverse events in melanoma:** Aims to better understand the skin reactions that sometimes occur during immunotherapy, and potentially reveal a way for clinicians to intervene earlier so patients do not discontinue or delay therapy.

**MRA-ACS Pilot Award**

- Suephy Chen, M.D., Emory University

**Clinical features and biomarkers of immunotherapy neurologic toxicity:** Seeks to better characterize, predict and determine the causes of neurological toxicities that occur in response to checkpoint immunotherapy.

**MRA-ACS Pilot Award**

- Bianca Santomasso, M.D., Ph.D., Memorial Sloan Kettering Cancer Institute

**Development of OncoLink: A web-based irAE monitoring platform:** Will determine if an evidence-based, online monitoring program can improve the care of cancer patients by offering ways to better manage the side effects of immunotherapy.

**MRA-ACS Pilot Award**

- Betina Yanez, Ph.D., Northwestern University
MRA General RFP Awards
MRA issues a general Request for Proposals (RFP) once a year during late summer/fall. The 2017 RFP invited applications for Team Science (up to $900,000 over 3 years) and Young Investigator Awards (up to $225,000 over 3 years). Special emphasis areas included: treatment failure or difficult-to-treat disease; developing markers of response, resistance or risk of recurrence; informing logical and optimal combination and/or therapeutic sequences; and identification of new targets, treatments or biomarkers. As a result, the following awards were issued in 2018:

Team Science Awards
Targeting BAP1-dependent alterations in metastatic uveal melanoma: Takes an integrated team approach to understand how mutations in a gene, known as BAP1, drive uveal melanoma cells to metastasize.

The Helman Family-MRA Team Science Award
- Andrew Aplin, Ph.D., Thomas Jefferson University
- Emily Bernstein, Ph.D., Icahn School of Medicine at Mount Sinai
- J. William Harbour, M.D., Sylvester Comprehensive Cancer Center/University of Miami Health Systems
- Marlana Orloff, M.D., Thomas Jefferson University: Young Investigator

Diet, mental health, and the microbiome in response to immunotherapy: Aims to build upon existing research to further explore how the collection of microorganisms living within the digestive tract, known as the gut microbiome, could be modified to improve outcomes for patients with metastatic melanoma.

MRA Team Science Award, collaboratively funded by University of Texas M.D. Anderson Cancer Center
- Lorenzo Cohen, Ph.D.
- Jennifer Wargo, M.D.
- Jennifer Leigh McQuade, M.D., Young Investigator

Autophagy in the tumor microenvironment as a target for drug development: Investigates whether blocking the natural “self-cleaning” process that occurs within tumors can enhance the killing to tumors by immune cells.

The Anna-Maria and Stephen Kellen Foundation-MRA Team Science Award
- Hilary A. Coller, Ph.D.
- Lili Yang, Ph.D.
- Claudio Scafoglio, M.D., Ph.D., Young Investigator

Cedars-Sinai Medical Center
- Beatrice Knudsen, M.D., Ph.D.

Commensal microbiota and anti-PD-1 efficacy: Aims to identify the exact species of “good” bacteria that help improve a patient’s response to immunotherapy treatment, with the hope of developing a novel therapy to improve immunotherapy efficacy in melanoma patients.
MRA Team Science Award, collaboratively funded by The University of Chicago.

The University of Chicago
  • Thomas Gajewski, M.D., Ph.D.,
  • Jason Luke, M.D.,
  • Cathryn Nagler, Ph.D.,
  • Riyue Bao, Ph.D., Young Investigator

Identifying genetic dependencies in rare forms of melanoma: Will use state-of-the-art gene editing tools to identify and characterize new drug targets in rare forms of melanoma.

MRA Team Science Award
  • Nicholas Hayward, Ph.D., Queensland Institute of Medical Research
  • Francisca Vasquez, Ph.D., Broad Institute

• Ken Dutton-Regester, Ph.D., Queensland Institute of Medical Research: Young Investigator

Prognostic and functional roles of altered circular RNAs in melanoma: Aims to take a closer look at loop-shaped RNA molecules, called circular RNAs or circRNA, to study how they are controlled within the body, as well as investigate their potential as drug targets for melanoma and predictors of melanoma progression.

Leveraged Finance Fights Melanoma-MRA Team Science Award
  • Eva Hernando, Ph.D., New York University School of Medicine
  • Ernesto Guccione, Ph.D., Icahn School of Medicine at Mount Sinai

Next-generation neoantigen-targeting peptide vaccines for melanoma patients: Will further optimize design and delivery of a personalized anti-cancer vaccine called NeoVax to improve melanoma control and cure.
Targeting eIF4A in melanoma persistent cells to prevent resistance: Plans to further study a specific protein, called eIF4A, which drives melanoma resistance to combination targeted therapies, with the goal of designing a clinical trial to delay treatment resistance in patients with BRAF mutant melanoma.

Directing adaptive immune responses to non-polymorphic MHCs in melanoma: Aims to address challenges around personalized approaches to immunotherapy by identifying and testing a new class of immunotherapy targets, which are called HLA-E in humans and Qa-1 in mice.

DAMPening immunotherapy adverse events in melanoma: Will test whether the immune system’s response to tissue damage is a major contributor to immune-related adverse events, and then develop a clinical trial to test potential therapies for mitigating these side effects in patients with melanoma.

Young Investigator Awards
Building a predictive framework for vaccine design against melanoma: Will combine mathematical models and lab experiments to build a prediction tool that yields the most rationale drug combinations for vaccines designed for melanoma.

Dr. Stephanie Dougan in her lab at Dana Farber Cancer Institute
Manipulating cellular metabolism to promote cancer immunity in melanoma: Aims to use innovative techniques to identify promising drug targets within the tumor microenvironment, which has potential to expand immunotherapy treatment options for patients.

The Robbins Family-MRA Young Investigator Award
- Ku-Lung Hsu, Ph.D., The University of Virginia

Investigating the mechanistic basis for tumor immunogenicity in melanoma: Will build novel animal models that allow researchers to study the anti-tumor immune response and to understand why melanomas often respond to immunotherapy whereas many other cancer types do not.

The Sokoloff Family-MRA Young Investigator Award
- Nikhil Joshi, Ph.D., Yale University

LncRNAs as modulators of protein synthesis rewiring in melanoma: Aims to test the potential of molecules called the long non-coding RNAs (lncRNAs) as a druggable targets to overcome therapeutic resistance.

Amanda and Jonathan Eilian-MRA Young Investigator Award
- Eleonora Leucci, Ph.D., Katholieke Universiteit Leuven

Primary anogenital melanoma: Comprehensive molecular and immune analysis: Will undertake a study to look at a rare but aggressive melanoma subtype called anorectal melanoma (AM) and identify factors that are linked to patient outcomes.

MRA Young Investigator Award, collaboratively funded by University of Texas M.D. Anderson Cancer Center
- Priyadharsini Nagarajan, M.D., Ph.D., University of Texas M.D. Anderson Cancer Center

Isoform-specific targeting of the PI3Ks to overcome cancer immuno-resistance: Seeks to better understand the role of PI3Ks, a group of enzymes known to play a key role in helping tumor cells escape the immune system’s attack, and then will target them therapeutically to enhance the effectiveness of immunotherapy.

MRA Young Investigator Award, collaboratively funded by University of Texas M.D. Anderson Cancer Center
- Weiyi Peng, Ph.D., University of Houston

Dependence of melanoma metastasis on AMPK-mediated metabolic switch: Aims to identify novel pathways that allow melanoma cells to survive under metabolic stress in the blood and in new tumor sites, with the hope of developing a therapy that specifically targets tumors that have spread to other places in the body.

Ellen and Gary Davis Foundation-MRA Young Investigator Award, collaboratively funded by Joan & Sanford I. Weill Medical College of Cornell University
- Elena Piskounova, Ph.D., Joan & Sanford I. Weill Medical College of Cornell University

The genomic landscape of individual melanocytes from human skin: Will collect and organize data on the genetic features of normal, individual melanocytes, which are the cells from which melanomas form, to better understand how melanoma arises at the molecular level.

Tara Miller Melanoma Foundation-MRA Young Investigator Award
- Hunter Shain, Ph.D., University of California, San Francisco
Targeting PSGL-1 inhibitory pathways to promote anti-tumor T cell immunity: Plans to test whether blocking a molecule called PSGL-1 will restore the T cell’s natural ability to kill melanoma cells.

The Denise and Michael Kellen Foundation-MRA Young Investigator Award

- Roberto Tinoco, Ph.D., University of California, Irvine

Pilot study of intervention to reduce sunburns in melanoma survivors: Will pilot test whether a wearable device that tracks sun exposure and provides alerts regarding sun exposure and protection behaviors will reduce sunburns in melanoma survivors.

The Wayne Stinchcomb Big Orange Foundation-MRA Young Investigator Award

- Rachell Vogel, Ph.D., The University of Minnesota - Twin Cities

Targeting the JNK-ITCH signaling pathway in melanoma: Aims to understand how tumor cells reprogram chemical reactions in a cell to gain growth advantage and escape death from anti-cancer drugs.

Mary Jo and Brian Rogers-MRA Young Investigator Award

- Lixin Wan, Ph.D., H. Lee Moffitt Cancer Center & Research Institute

Developing advanced non-invasive histology techniques: Combines artificial intelligence and digital imaging technology to conduct ‘virtual biopsies’ of potential melanomas, as an alternative to less safe laser techniques.

Brownstein, Hyatt, Farber, & Schreck-MRA Young Investigator Award

- Jesse Wilson Ph.D., Colorado State University

Targeting BRAF/NRAS wildtype melanoma with ERBB3 and MEK inhibition: Seeks to address the unmet needs of non-BRAF mutant melanoma patients who have limited treatment options by conducting a clinical trial to evaluate a promising combination molecular therapy.

MRA Young Investigator Award, collaboratively funded by Thomas Jefferson University

- Melissa Wilson, M.D., Ph.D., Thomas Jefferson University
ANNUAL REPORT
RECOGNITION LISTS
DONORS FISCAL YEAR 2017

$500,000+
- Debra and Leon Black
- BJ's Wholesale Club
- Bristol-Myers Squibb Company
- The Helman Family
- Anna-Maria and Stephen Kellen Foundation
- Paul, Weiss, Rifkind, Wharton & Garrison LLP
- Sokoloff Family Trust
- US Trust

$250,000-$499,999
- Ellen and Gary Davis Foundation
- Amanda and Jonathan Eilian Goldman Sachs & Co.
- Merck & Co., Inc.
- Tara Miller Melanoma Foundation
- Julie and Edward Minskoff PricewaterhouseCoopers
- Mary Jo and Brian Rogers Saban Family Foundation
- Sotheby's

$100,000-$249,999
- Nicholas Acquavella
- Akin Gump Strauss Hauer & Feld LLP
- Anonymous
- Aon Foundation
- Jill and Jay Bernstein Brownstein, Hyatt, Farber & Schreck LLP
- Christie's
- Deloitte
- Gail and Dick Elden
- Katherine Farley and Jerry Speyer
- Susan and John Hess
- Elias Kefalidis
- Kirkland & Ellis LLP
- The Ronald & Jo Carole Lauder Foundation
- Karen Mack and Russell Goldsmith
- Nancy and Howard Marks
- Jane and Daniel Och
- Ruth and Elliot Sigal
-erry and James Tisch
- Veritas Capital Management LLC
- Vinson & Elkins LLP
- Wachtell, Lipton, Rosen & Katz

$50,000-$99,999
- Amgen, Inc.
- Bloomberg L.P.
- Chrissie Erpf and Larry Gagosian
- Fitch Ratings
- Audrey and Martin Gruss
- Judy and John Hannan
- Jane Heller
- William Helman
- Ronnie Heyman and Ward Blum
- Incyte Corporation
- Ipreo
- The Kraft Family Foundation
- Latham & Watkins LLP
- Bennet S. LeBow
- Leonard Green & Partners, LLP
- L'Oréal Paris
- Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC
- Novartis Corporation
- Paul Hastings LLP
- Cynthia and Leon Polsky
- Harley and Robert Raiff
- Francine and Jeffrey Rowbottom
- Simpson Thacher & Bartlett LLP
- Paul Singer
- Sanjay Thapar

$25,000-$49,999
- Anonymous
- Array BioPharma
- Debbie and Mark Attanasio
- Jessica and Natan Bibliowicz
- Emily and Len Blavatnik
- The Brown Foundation, Inc., of Houston
- Cahill Gordon & Reindel LLP
- Continental Grain Company
- Jennifer Corwin and Lee Grinberg
- Daiichi Sankyo
- Judith and James Dimon
- Caryl and Israel Englander
- Ernst & Young
- Gibson, Dunn & Crutcher LLP
- Guggenheim Partners
- Immunocore
- Johnson & Johnson
- Barbara Kannapell
- Laurie Kefalidis
- Kramer Levin Naftalis & Frankel LLP
- Abby Leigh
- Macquarie Group
- Morgan, Lewis & Bockius LLP
- Morgan Stanley
- O'Melvey & Myers LLP
- Shearman & Sterling LLP
- Skadden, Arps, Slate, Meagher & Flom LLP
- SkinCeuticals
- Society for Immunotherapy of Cancer
- The Wayne Stinchcomb Big Orange Foundation
- The Thompson Family Foundation, Inc.
- Jill and Christopher Torrente Teri and Trevor Watt
- Sara and Scott Weiner
- Wells Fargo Bank

$10,000-$24,999
- Allen & Overy
- American Industrial Partners
- Ares Management LLC
- Barclays
- Kelly Behun Sugarman and Jay Sugarman
- Ronit and William Berkman
Blackstone Group LP
The Blue Oak Charitable Fund
BMO Capital Markets
Michele and Fred Brettschneider
Castle Biosciences, Inc.
Celldex Therapeutics, Inc.
Checkmate Pharmaceuticals
Clayton, Dubilier & Rice LLC
Joyce and Barry Cohen
Frank Courtney
Cravath, Swaine & Moore LLP
Credit Suisse
Crescent Capital Group
Davis Polk & Wardwell
Debevoise & Plimpton LLP
Deutsche Bank
Eva and Brendan Dillon
Marcus Dougherty
EMD Serono, Inc.
Fried, Frank, Harris, Shriver & Jacobson LLP
Genentech, Inc.
Mimi Haas
The Ronnie F. Heyman Foundation LLC
HSBC Bank
Maria Hummer-Tuttle and Bob Tuttle
Idera Pharmaceuticals
Mark Jenkins
Jones Management Consulting, Inc.
George W. and Elizabeth W. Kelly Foundation, Inc.
Tom Keyes and Keith Fox
Kohlberg Kravis Roberts & Co.
KPMG LLP
Ashley Leeds and Christopher Harland
Susan Logan Evensen and Peter Evensen
Loxo Oncology
Nancy Marcus
Jane Trapnell Marino and Peter Marino
Mayer Brown LLP
Milbank Tweed Hadley & McCloy LLP
Mizuho Bank USA
Mizuho Securities USA, Inc.
MJX Asset Management LLC
Debbie and George Miller
Julie and Kenneth Moelis
The Neiman Marcus Group
New Mountain Finance Corporation
Patty Newburger and Brad Wechsler
Nomura Securities
Oak Hill Advisors, LP
OncoSec Medical
Orchard First Source Asset Management
Owl Rock Capital Partners LP
Phaidon Press
Peggy and Gary Reiner
Rgenix
Robbins Family Foundation
Ropes & Gray LLP
Royal Bank of Canada
Royalty Pharma
David Solomon
Sony Music
Allison and Leonard Stern
Jennifer and David Stockman
Sullivan & Cromwell LLP
Suveretta Capital Management
Hope and Glenn Taitz
Thoma Bravo
TPG Capital, L.P.
Utay Family Foundation
Weil, Gotshal & Manges LLP
White & Case LLP
$5,000-$9,999
Allure
American Securities Advisors LLC
Anonymous
Antares Capital LP
Renee and Richard Barasch
Barings LLC
Jill and Jay Bernstein Family Foundation
Birds Nest Productions
Katherine Boden Holland and David Holland
Jim Bonetti
Melanie and Stephen Brody
Campbell Brown and Daniel Senor
Richard Brown
Bradley Butwin
Thomas Cole
Thomas Connolly
Connolly’s Pub & Restaurant
CreditSights
CVC Capital Partners
DDJ Capital Management, LLC
Debra Black
John Hess
DLA Piper
William C. Dowling, Jr. Foundation
Joshua Easterly
Freedom Mortgage
Scot French
Golden Gate Capital
GoldenTree Asset Management, LP
GTCR
Lauren Hanrahan
HPS Investment Partners, LLC
Rhonda and Stratton Heath
Rich Hogan
Holland & Knight
William Janetschek
Jefferies LLC
Mitchell Kline
Sarah and Stewart Kagan
LCD/Standard & Poor
LSTA/Loan Syndications & Trading Association
Peter Lyon
Laurie and Peter Maglathlin
Leslie and Tom Maheras
Christina Minnis
Margo and James Nederlander
Oak Hill Capital Management
Onex Credit Partners
The Palermo-Ravich Foundation
PJT Partners
Physicians Health Center
Proskauer Rose LLP
Ellen and Bruce Ressler
Jonathan Ressler
David Rickles
Jonathan Rosenberg
Eric Rothenberg
The Lawrence and Carol Saper Foundation, Inc.
Nicole Seligman and Joel Klein
Shenman Capital Management, Inc.
Lindsi Shine
Plum and Jonathan Simons
Beatrice Stern
Dana and Andrew Stone
Stone Point Capital
Sumitomo Mitsui Banking Corporation
SunTrust Robinson Humphrey
Pamela Sztybel and Elliot Stein
Stephanie Teicher
Fern and Lenard Tessler
Teri and Barry Volpert
Fern and George Wachter
Warburg Pincus LLC
Jeremiah Whiddon

$1,000-$4,999
The Bank of America Charitable Foundation, Inc.
Vivek Bantwal
Vanessa Brown
Dana Carey
Kristen and Didric Cederholm
John Coban
Judith Cohen
Tad Cohn
Combined Federal Campaign
Co-Tan Family LLC
Bradley Cuddeback
Angela DeCesaris
Jeffrey Deitch
Kerry Dolan
Susan Drossman and Adam Sokoloff
Scott Edelman
Amine Ferchichi
Matt Fink
Joanne Franzel
Rondi and David Frieder
Fulcrum Financial LevFin Insights
Robert Fullerton
Andrea Geroldi
Jeffrey Greenip
Ellen and Benjamin Grinberg
Mary and Meyer Grinberg
Agnes Gund
Jeffrey Haber
Pearl and Nathan Halegua
Kim Heirston
Yasser Hussein
IBM Employee Services Center
Bruce Jackson
Boriana Karastoyanova
Joseph Kieffer
Jan and Edward Korenman
Andrew Kramer
Richard Kramer
Mark Krueger & Associates, Inc.
Adam Kurzer
Robert Lewin
Julie and David McKenna
Kathleen Moe
Grant Moyer
George Mueller
Eric Muller
Marion and David Mussafer
Linda and Dennis Myers
Natixis Global Asset Management
Network Financial Printing, Inc.
Kimberly O’Malley
David Perdue
Christopher Pike
Ken Prince
William Rahm
Hilary Rogers
Bruce Rokjer
The Pamela and Arthur Sanders Family Foundation Inc.
Haley Satnick
Matthew Savino
David Scudellari
MCraig Shepherd
Shethar Foundation
Carren and Dean Shulman
Woody Simonds
Adam Smith
Deby and James Staley
Martha Stewart
Amanda Taitz
Andrea and Russell Thomas
William Thompson
Adele Thurnher
Margot Usdain
Allison and Ray Vuicich
James Walsh
Carol and Michael Weisman
Shelby White
Constance and Sankey Williams
Brian Wolfe

Full list of all donors available online
# STATEMENT OF FINANCIAL POSITION

## ASSETS

<table>
<thead>
<tr>
<th></th>
<th>Total 2017</th>
<th>Total 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalents</td>
<td>$14,121,998</td>
<td>$22,555,754</td>
</tr>
<tr>
<td>Investments</td>
<td>10,219,557</td>
<td></td>
</tr>
<tr>
<td>Contributions Receivable (Net)</td>
<td>18,009,454</td>
<td>$8,288,256</td>
</tr>
<tr>
<td>Due from Affiliate</td>
<td>–</td>
<td>$1,260</td>
</tr>
<tr>
<td>Prepaid Expenses</td>
<td>75,043</td>
<td>$33,604</td>
</tr>
<tr>
<td>Property and Equipment (Net)</td>
<td>–</td>
<td>$3,579</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td><strong>$ 42,426,052</strong></td>
<td><strong>$ 30,882,453</strong></td>
</tr>
</tbody>
</table>

## LIABILITIES

<table>
<thead>
<tr>
<th></th>
<th>Total 2017</th>
<th>Total 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts Payable</td>
<td>$137,004</td>
<td>$74,168</td>
</tr>
<tr>
<td>Grants Payable (Net)</td>
<td>$11,848,581</td>
<td>$13,204,967</td>
</tr>
<tr>
<td>Deferred Revenue</td>
<td>$57,240</td>
<td>$110,000</td>
</tr>
<tr>
<td>Due to Affiliate</td>
<td>$16,744</td>
<td>–</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td><strong>12,059,569</strong></td>
<td><strong>13,389,135</strong></td>
</tr>
</tbody>
</table>

## NET ASSETS

<table>
<thead>
<tr>
<th></th>
<th>Total 2017</th>
<th>Total 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>$12,357,029</td>
<td>$9,205,062</td>
</tr>
<tr>
<td>Temporarily Restricted</td>
<td>18,009,454</td>
<td>8,288,256</td>
</tr>
<tr>
<td><strong>TOTAL NET ASSETS</strong></td>
<td><strong>30,366,483</strong></td>
<td><strong>17,493,318</strong></td>
</tr>
</tbody>
</table>

**TOTAL LIABILITIES AND NET ASSETS**

<table>
<thead>
<tr>
<th></th>
<th>Total 2017</th>
<th>Total 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>$ 42,426,052</strong></td>
<td><strong>$ 30,882,453</strong></td>
</tr>
</tbody>
</table>
### STATEMENT OF ACTIVITIES

#### REVENUE & EXPENSE STATEMENT

<table>
<thead>
<tr>
<th></th>
<th>Total 2017</th>
<th>Total 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>REVENUE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions (Collectible Net)</td>
<td>$2,841,125</td>
<td>$6,171,125</td>
</tr>
<tr>
<td>Special Events (Net)</td>
<td>$20,832,080</td>
<td>$1,374,162</td>
</tr>
<tr>
<td>Sponsorship</td>
<td>$455,000</td>
<td>$526,300</td>
</tr>
<tr>
<td>Interest/Investment</td>
<td>$291,322</td>
<td>$66,405</td>
</tr>
<tr>
<td>In-Kind Contributions</td>
<td>$142,336</td>
<td>$101,959</td>
</tr>
<tr>
<td>Other Income</td>
<td>$21,100</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL REVENUES</strong></td>
<td>$24,582,963</td>
<td>$8,239,951</td>
</tr>
</tbody>
</table>

|                          |                 |                 |
| **EXPENSES:**            |                 |                 |
| Research Grants          | $9,079,591      | $20,602,554     |
| Personnel Costs          | $1,412,640      | $1,009,088      |
| Travel & Entertainment   | $309,836        | $273,626        |
| Other Expenses           | $306,803        | $224,324        |
| Meetings & Conferences   | $251,405        | $208,055        |
| Professional Fees        | $210,636        | $137,202        |
| Occupancy                | $138,887        | $155,686        |
| **TOTAL EXPENSES:**      | $11,709,798     | $22,610,535     |
| **NET INCOME/(LOSS)**    | $12,873,165     | ($14,370,584)   |

#### MRA FUNCTIONAL EXPENSES

- **$315,625** Management & Admin
- **$657,551** Fundraising
- **$1,657,031** Non-Grant Program Expenses
- **$9,079,591** Research Grants

- **92%** Total Program Costs
- **78%** Research Grants
- **5%** Fundraising
- **3%** Management & Admin
**MRA BOARD OF DIRECTORS**

Debra R. Black  
Debra Black  
Co-Founder & Chair, MRA  
Broadway Producer

Leon Black  
Co-Founder, MRA  
Chairman & CEO  
Apollo Global Management, LLC

Benjamin Black  
Vice President  
OCV Partners

Margaret Anderson  
Secretary, MRA Board  
Managing Director, Deloitte

Maria Bell  
Television Writer  
Television Producer

Ellen Davis  
Principal  
Makana Beverages

Amanda Eilian  
Co-Founder and President  
Videolicious, Inc.

Jason Daniel Federici  
Art Director and Designer

Jami Gertz  
Television and Film Actress

Daisy Helman  
CEO and Founder  
Garden Collage

Susan Hess  
Vice Chairman  
Whitney Museum

Denise Kellen  
Patient Advocate  
Philanthropist

Michael Klowden  
CEO  
Milken Institute

Nancy Marks  
Chairman, Sies Marjan

Michael Milken  
Chair, Milken Institute  
Founder & Chair, FasterCures & Prostate Cancer Foundation

Richard Ressler  
Founder & President of  
Orchard Capital Corporation and CIM Group

Mary Jo Rogers  
Melanoma Patient  
Melanoma Advocate

Jeffrey Rowbottom  
Managing Director  
PSP Investments

Elliott Sigal, M.D., Ph.D.  
Senior Advisor/Venture Partner  
New Enterprise Associates

Jonathan W. Simons, M.D.  
President and CEO  
Prostate Cancer Foundation

Jonathan Sokoloff  
Managing Partner  
Leonard Green & Partners, LP

Elizabeth Stanton  
President  
The Elizabeth and Oliver Stanton Foundation

Suzanne L. Topalian, M.D.  
Professor, Surgery and Oncology  
Johns Hopkins Medicine

**MRA STAFF**

Michael Kaplan  
President and CEO

Louise Perkins  
Chief Science Officer

Joan Russo  
Chief Development Officer

Kristen Mueller  
Scientific Program Director

Cody Barnett  
Director of Communications

Janine Rauscher  
Associate Director, Development & Information Management

Tasheema Prince  
Scientific Program Manager

Subira Brown  
Development Associate

Tyler Brown  
Patient Engagement & Operations Associate
SCIENTIFIC ADVISORY PANEL

Suzanne Topalian, M.D. (Chair)  
Professor, Surgery and Oncology,  
Johns Hopkins Medicine  
Director, Melanoma Program,  
Kimmel Cancer Center  
Associate Director, Bloomberg–Kimmel Inst.  
for Cancer Immunotherapy

Jeff Allen, Ph.D.  
President and CEO, Friends of Cancer Research

James P. Allison, Ph.D.  
Professor and Chair of Immunology  
University of Texas MD Anderson Cancer Center

Boris Bastian, M.D.  
Clinical Professor, Department of Dermatology  
University of California, San Francisco

Gideon Bollag, Ph.D.  
Chief Executive Officer, Plexxikon, Inc.

Glenn Dranoff, M.D.  
Global Head of Exploratory Immuno-Oncology  
Novartis Pharmaceuticals Corporation

Levi Garraway, M.D., Ph.D.  
Senior Vice President, Global Development & Medical Affairs, Lilly Oncology, Eli Lilly and Company

Allan C. Halpern, M.D.  
Chief, Dermatology Service, Memorial Sloan Kettering Cancer Center

Reid Huber, Ph.D.  
Executive Vice President,  
Chief Scientific Officer  
Incyte Corporation

Nageatte Ibrahim, M.D.  
Development Lead, Merck Research Laboratories

Jeffrey Legos, Ph.D.  
Senior Vice President, Global Program Head, Novartis Pharmaceuticals Corporation

Richard Marais, Ph.D., FMedSci  
Director,  
Cancer Research UK Manchester Institute

Ira Mellman, Ph.D.  
Vice President of Research  
Oncology, Genentech

Fouad Namouni, M.D.  
Senior Vice President and Head of Oncology Development, Bristol-Myers Squibb

David Reese, M.D.  
Senior Vice President,  
Translational Science, Amgen, Inc.

Neal Rosen, M.D., Ph.D.  
Enid A. Haupt Chair in Medical Oncology, Memorial Sloan Kettering Cancer Center

Steven Rosenberg, M.D.  
Chief, Surgery Branch - National Cancer Institute, National Institutes of Health

Michael Weber, Ph.D.  
Director, Cancer Center, Weaver Professor of Oncology, University of Virginia

MELANOMA > EXCHANGE COMMUNITY LEADERS

Dr. Jedd Wolchok

Melanoma > Exchange, available at www.curemelanoma.org/community is a vibrant online community led by patients and caregivers with firsthand understanding of melanoma and clinical trials and experts from the MRA staff. Together, these community leaders have cultivated a unique environment where patients can get true insight into key milestones such as being diagnosed, choosing and going through treatment or finding the right clinical trial, and addressing any implications with friends and family.
MEDICAL ADVISORY PANEL

Dermatology

David Fisher, M.D., Ph.D.
Edward Wigglesworth Professor & Chairman
Dept of Dermatology
Director, Melanoma Program MGH
Cancer Center
Director, Cutaneous Biology Research Center
Massachusetts General Hospital
Harvard Medical School

Sancy Leachman, M.D., Ph.D.
Director, Melanoma Research Program,
Knight Cancer Institute

Roger Lo, M.D., Ph.D.
Professor, Departments of Medicine &
Molecular and Medical Pharmacology, UCLA
David Geffen School of Medicine and Jonsson
Comprehensive Cancer Center

David Polsky, M.D., Ph.D.
Professor of Dermatology
and Pathology
Director, Pigmented Lesion Section
NYU Langone Medical Center
Joan and Joel Smilow Research Center

Susan Swetter, M.D.
Professor of Dermatology
Director, Pigmented Lesion & Melanoma
Program
Stanford University Medical Center and Cancer
Institute

Medical Oncology

Michael Atkins, M.D.
Deputy Director, Georgetown-Lombardi Cancer
Center, Georgetown University

Paul Chapman, M.D.
Attending Physician, Melanoma / Sarcoma
service, Memorial Sloan-Kettering
Cancer Center
Professor of Medicine, Weill Medical College of
Cornell University

Thomas Gajewski M.D., Ph.D.
Professor, Departments of Pathology and
Medicine, University of Chicago

F. Stephen Hodi, M.D.
Assistant Professor, Department of Medicine,
Harvard Medical School Assistant Professor of
Medicine,
Dana-Farber Cancer Institute

Patrick Hwu, M.D.
Department Chair, Department of Melanoma
Medical Oncology, Division Head, Cancer
Medicine, The University of Texas MD
Anderson Cancer Center

Kim Margolin, M.D.
Clinical Professor, City of Hope National
Medical Center

Antoni Ribas, M.D., Ph.D.
Professor of Medicine
University of California, Los Angeles

Lynn Schuchter, M.D., Chair
C. Willard Robinson Professor of Hematology-
Oncology
Attending Physician, Hospital of the University
of Pennsylvania
Program Leader: Melanoma Program,
Abramson Cancer Center of the University of
Pennsylvania
Division Chief, Hematology-Oncology,
University of Pennsylvania
Jeffrey S. Weber, M.D., Ph.D.
Deputy Director and Head, Experimental Therapeutics, Laura and Isaac Perlmutter Cancer Center
Professor of Medicine at the NYU Langone Medical Center

Jedd Wolchok, M.D., Ph.D.
Associate Professor
Memorial Sloan-Kettering Cancer Center

Surgical Oncology

Charlotte Ariyan, M.D.
Associate Attending, Memorial Sloan Kettering Cancer Center

Jeffrey Gershenwald, M.D.
Professor, University of Texas, M.D. Anderson Cancer Center

Howard Kaufman, M.D.
Professor of Surgery, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey

Suzanne Topalian, M.D.
Professor, Surgery and Oncology, Johns Hopkins Medicine Director, Melanoma Program, Kimmel Cancer Center Associate Director, Bloomberg–Kimmel Institute for Cancer Immunotherapy

Dr. Yvonne Saenger

Drew Pardoll and Jonathan Simons
GRANT REVIEW COMMITTEE

Martin McMahon Ph.D. Chair
Cumming-Presidential Professor of Cancer Biology, Department of Dermatology & Senior Director for Preclinical Translation
Huntsman Cancer Institute, University of Utah

Jennifer Wargo, M.D. Co-Chair
Assistant Professor, Department of Surgical Oncology, Division of Surgery, the University of Texas MD Anderson Cancer Center

Andrew Aplin, Ph.D.
Professor, Department of Cancer Biology, Thomas Jefferson University
Associate Director for Basic Science Program Leader for Cancer Cell Biology and Signaling, Kimmel Cancer Center

Boris Bastian, MD, PhD.
Leader, Cutaneous Oncology
University of California, San Francisco
Nina Bhardwaj, MD, PhD
Director, Immunotherapy Program
Ichan School of Medicine at Mount Sinai

Nina Bhardwaj, M.D., Ph.D.
Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai

Marcus Bosenberg, M.D., Ph.D.
Associate Professor of Dermatology and Pathology, Yale School of Medicine

Steven Burakoff, M.D.
Director, Tisch Cancer Institute Professor of Medicine, Hematology and Medical Oncology Professor, Oncological Sciences, Icahn School of Medicine at Mount Sinai

Paul B. Chapman, M.D.
Associate Physician, Melanoma/Sarcoma service
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Medical College of Cornell University

Charles Drake, M.D., Ph.D.
Director Genitourinary Oncology Co-Director Immunotherapy Associate Director, Herbert Irving Comprehensive Cancer Center Columbia University Medical Center

David Fisher, M.D., Ph.D.
Edward Wigglesworth Professor & Chairman Dept of Dermatology
Director, Melanoma Program MGH Cancer Center
Director, Cutaneous Biology Research Center Massachusetts General Hospital
Harvard Medical School

Keith Flaherty, M.D.
Director, Henri and Belinda Termeer Center for Targeted Therapies
Richard Saltonstall Chair in Oncology, Massachusetts General Hospital Cancer Center

Thomas Gajewski M.D., Ph.D.
Professor, Departments of Pathology and Medicine, University of Chicago
Director, Immunology and Cancer Program, University of Chicago Comprehensive Cancer Center

Jeffrey Gershenwald, M.D.
Professor, University of Texas M.D. Anderson Cancer Center

Tanja de Gruijl, Ph.D.
Professor, Translational Tumor Immunology and Head Immunotherapy Lab
VU University Medical Center, Amsterdam

J. William Harbour, M.D.
Professor and Vice Chairman, Dr. Mark J. Daily Endowed Chair, Director of Ocular Oncology, Bascom Palmer Eye Institute
Member, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine

Meenhard Herlyn, D.V.M., D.Sc.
Professor and Program Leader, Molecular and Cellular Oncogenesis Program
Wistar Institute

Thomas J. Hornyak, M.D., Ph.D.
Chief of Dermatology, VA Maryland Health Care System
Associate Professor of Dermatology and
Biochemistry and Molecular Biology
University of Maryland School of Medicine

Roger Lo, M.D., Ph.D.
Professor, Departments of Medicine & Molecular and Medical Pharmacology
UCLA David Geffen School of Medicine and Jonsson Comprehensive Cancer Center

Michal Lotem, M.D.
Head, Center for Melanoma and Cancer Immunotherapy
Sharett Institute of Oncology
Hadassah Hebrew University Medical Center

Kim Margolin, M.D.
Clinical Professor, City of Hope National Medical Center

Glenn Merlino, Ph.D.
Chief, Laboratory of Cancer Biology and Genetics
National Cancer Institute, NIH

Drew Pardoll, M.D., Ph.D.
Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics
John Hopkins University School of Medicine

Antoni Ribas, M.D., Ph.D.
Professor of Medicine, University of California, Los Angeles

Caroline Robert, M.D., Ph.D.
Professor of Dermatology, Head of the Dermatology Unit, Institute Gustave Roussy

Lynn Schuchter, M.D.
C. Willard Robinson Professor of Hematology-Oncology
Attending Physician, Hospital of the University of Pennsylvania
Program Leader: Melanoma Program, Abramson Cancer Center of the University of Pennsylvania
Division Chief, Hematology-Oncology, University of Pennsylvania

Jonathan Simons, M.D.
CEO and President
David H. Koch Chair
Prostate Cancer Foundation

Craig Slingluff, M.D.
Joseph Help Farrow Professor of Surgery, Division of Surgical Oncology
Vice Chair for Research
Director, Human Immune Therapy Center, University of Virginia

Maria Soengas, Ph.D.
Head, Melanoma Group, Dean for Academic Affairs, Spanish National Cancer Research Centre

David B. Solit, M.D.
Geoffrey Beene Chair
Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology
Attending Physician, Genitourinary Oncology Service
Member, Human Oncology and Pathogenesis Program
Memorial Sloan Kettering Cancer Center

Alan Spatz, M.D.
Professor, Jewish General Hospital/Lady Davis Institute for Medical Research

Hermann Steller, Ph.D.
Strang Professor and Investigator, Howard Hughes Medical Institute, The Rockefeller University

Susan M. Swetter, M.D.
Professor of Dermatology
Director, Pigmented Lesion & Melanoma Program
Physician Leader, Cancer Care Program in Cutaneous Oncology
Stanford University Medical Center & Cancer Institute

Suzanne Topalian, M.D.
Professor, Surgery and Oncology, Johns Hopkins Medicine
Director, Melanoma Program, Kimmel Cancer Center
Associate Director, Bloomberg-Kimmel Inst. for Cancer Immunotherapy

Jeffrey Weber, M.D., Ph.D.
Deputy Director and Head, Experimental Therapeutics, Laura and Isaac Perlmutter Cancer Center
Professor of Medicine at the NYU Langone Medical Center